Clinical Next-Generation Sequencing (NGS) & Oncology Panels: What Patients, Providers, and Healthcare Buyers Need to Know
A cancer diagnosis can leave clinicians facing a difficult question: which molecular changes actually matter for treatment? Testing a single gene at a time may miss important alterations, while ordering a broad panel can introduce higher costs, more complex results, and difficult interpretation.
Clinical next-generation sequencing (NGS) has become an important part of modern precision oncology because one test can examine many genomic alterations simultaneously. Some clinically validated panels can identify mutations, copy-number changes, gene rearrangements, and biomarkers that may help determine whether a patient could benefit from a particular therapy.
The challenge is choosing the right panel, specimen type, laboratory, and level of testing—without paying for information that will not change a clinical decision.
This guide explains how clinical NGS works, how oncology panels compare, what they can and cannot tell you, what affects pricing, and the questions worth asking before selecting a testing provider.
What Is Clinical Next-Generation Sequencing?
Clinical next-generation sequencing is a laboratory testing approach that analyzes DNA and/or RNA to identify genetic alterations relevant to a patient's medical condition.
In oncology, NGS is commonly used to examine tumor tissue or blood-derived circulating cell-free DNA for alterations that may influence diagnosis, prognosis, treatment selection, or clinical-trial eligibility.
Depending on the assay, an oncology NGS panel may evaluate:
- Single-nucleotide variants
- Small insertions and deletions
- Gene amplifications and deletions
- Gene fusions and rearrangements
- Microsatellite instability (MSI)
- Tumor mutational burden (TMB)
- Selected resistance mutations
- Germline variants, when the test is specifically designed for that purpose
The important distinction is that not every NGS panel tests for all of these features.
A smaller targeted panel may focus on genes with established clinical relevance, while a comprehensive panel can investigate hundreds of genes and multiple biomarker classes.
For example, the FDA describes FoundationOne CDx as a tumor-profiling test designed to identify alterations in 324 genes along with selected rearrangements and biomarkers including MSI. It has companion-diagnostic uses across multiple cancers and therapies.
That illustrates why the phrase "NGS test" alone is not enough when comparing providers.
Why Are Oncology NGS Panels Important?
Cancer is fundamentally a genetic disease, but not all cancers are genetically identical.
Two people can have tumors originating in the same organ yet have substantially different molecular alterations.
Those differences can influence:
- Which targeted therapies are relevant
- Whether a patient may qualify for a biomarker-defined treatment
- Whether a resistance mechanism is present
- Whether an inherited cancer predisposition should be investigated
- Whether a clinical trial may be appropriate
The FDA maintains a list of authorized companion diagnostic devices and currently includes multiple NGS-based oncology assays, including FoundationOne CDx, Guardant360 CDx, FoundationOne Liquid CDx, and TruSight Oncology Comprehensive.
This is an important point for healthcare buyers:
A broad commercial panel and an FDA-authorized companion diagnostic are not automatically interchangeable.
The clinical indication, specimen type, biomarker, and intended use matter.
How Does an Oncology NGS Panel Work?
The workflow typically follows several stages.
1. A Specimen Is Collected
The laboratory may receive:
- Tumor biopsy tissue
- Surgical tissue
- Formalin-fixed paraffin-embedded tissue
- Blood
- Bone marrow
- Other validated specimen types
The correct specimen depends on the assay.
2. Nucleic Acids Are Extracted
DNA and/or RNA is isolated from the specimen.
This step is more important than it sounds. Poor sample quality, insufficient tumor content, degradation, or inadequate nucleic-acid quantity can affect whether a test produces a useful result.
3. Sequencing Is Performed
The laboratory uses sequencing technology to read selected genomic regions.
Unlike older approaches that might investigate one alteration at a time, NGS allows many targets to be evaluated in parallel.
4. Bioinformatics Processing
Raw sequencing information is processed using computational pipelines.
The laboratory identifies candidate variants and applies quality-control filters.
5. Clinical Interpretation
The detected alterations are reviewed in the context of:
- Cancer type
- Variant characteristics
- Available evidence
- Treatment indications
- Clinical guidelines
- Relevant clinical trials
6. A Report Is Produced
The final report may classify findings according to their clinical significance and identify potentially relevant therapies or trials.
This last step is crucial.
Sequencing generates data; clinical interpretation turns data into information.
Tissue NGS vs. Liquid Biopsy: Which Is Better?
One of the most common purchasing and clinical questions is whether to choose tissue testing or a blood-based liquid biopsy.
The answer depends on the situation.
| Feature | Tissue NGS | Liquid Biopsy NGS |
|---|---|---|
| Sample | Tumor tissue | Blood/plasma |
| Invasiveness | Requires tissue acquisition | Minimally invasive blood draw |
| Tumor DNA | Directly sampled from tissue | Circulating tumor DNA may be present |
| Repeat testing | More difficult | Generally easier |
| Main challenge | Tissue availability and quality | Low or absent circulating tumor DNA |
| Useful for | Broad tumor profiling when tissue is available | Selected situations requiring less invasive or repeat testing |
| Main limitation | Biopsy may be difficult or insufficient | A negative result may not exclude an alteration |
Liquid biopsy has become increasingly important in precision oncology.
Guardant360 CDx, for example, is an FDA-authorized assay based on circulating cell-free DNA and has multiple oncology companion-diagnostic indications. FDA records include indications involving EGFR, KRAS, ERBB2/HER2, ESR1, BRAF, and other biomarkers in specific cancer and treatment contexts.
The Critical Limitation of Liquid Biopsy
A blood test does not necessarily contain enough tumor-derived DNA to identify every alteration.
Therefore:
A negative liquid-biopsy result does not always mean that the tumor lacks a potentially relevant mutation.
Depending on the clinical situation, tissue testing may still be appropriate.
The decision should be made by the treating clinical team rather than by choosing whichever test appears cheapest or most convenient.
Comprehensive vs. Targeted Oncology Panels
Not every patient needs the largest available panel.
Targeted Panel
A targeted panel examines a selected group of genes or biomarkers.
Advantages:
- Focused testing
- Potentially lower complexity
- Often faster interpretation
- Useful when a defined clinical question exists
Disadvantages:
- May miss alterations outside the panel
- Can require additional testing later
- Less useful when the diagnosis or treatment strategy is uncertain
Comprehensive Panel
A comprehensive panel examines a substantially larger set of genes and may include multiple biomarker types.
Advantages:
- Broader molecular information
- Can identify less obvious therapeutic opportunities
- May reduce the need for multiple sequential tests
- Potentially useful for advanced or treatment-resistant disease
Disadvantages:
- Higher interpretive complexity
- More findings of uncertain significance may appear
- Can cost more
- Not every detected alteration has a proven treatment implication
The best choice depends on the clinical question.
A premium comprehensive test is not automatically "better" if the additional information will not change management.
What Are the Best Clinical NGS Oncology Panels?
There is no universal best panel.
The strongest options depend on cancer type, specimen, biomarker requirements, regulatory status, turnaround time, geographic availability, reimbursement, and the intended clinical decision.
Several established platforms deserve consideration.
FoundationOne CDx
FoundationOne CDx is a broad tissue-based tumor profiling assay from Foundation Medicine.
FDA documentation describes analysis of 324 genes, selected gene rearrangements, and biomarkers including MSI, with companion-diagnostic applications across several cancers and therapies.
Potential strengths
- Broad genomic profiling
- Established clinical use
- Multiple companion-diagnostic indications
- Useful for biomarker-driven treatment decisions
Potential drawbacks
- Broad testing may reveal findings that require expert interpretation
- Not every alteration is actionable
- Tissue quality remains important
FoundationOne Liquid CDx
FoundationOne Liquid CDx analyzes circulating cell-free DNA from blood.
It can be attractive when tissue is difficult to obtain or when a less invasive approach is clinically appropriate.
FDA records describe its use in identifying mutations associated with specific treatment decisions, including indications involving NSCLC and EGFR alterations.
Potential strengths
- Blood-based
- Less invasive than biopsy
- Useful when tissue is limited
- Can support selected treatment decisions
Potential limitation
A blood-based test depends on sufficient circulating tumor-derived DNA.
Guardant360 CDx
Guardant360 CDx is another major liquid-biopsy option.
FDA records show an expanding set of companion-diagnostic indications. In June 2026, for example, an FDA supplement added a companion-diagnostic indication involving ERBB2/HER2 activating mutations in NSCLC for treatment with zongertinib.
Potential strengths
- Blood-based testing
- Broad clinical footprint
- Multiple biomarker-specific treatment indications
- Useful when tissue acquisition is challenging
Potential limitation
Clinical interpretation depends on the exact indication and detected alteration; a broad report does not mean every result is treatment-defining.
TruSight Oncology Comprehensive
Illumina's TruSight Oncology Comprehensive is a broad tissue-based assay.
FDA documentation states that it evaluates DNA alterations across 517 genes and RNA alterations across 25 genes in solid tumor tissue. Its approved companion-diagnostic uses include NTRK1/2/3 fusions and RET fusions in specified clinical contexts.
Potential strengths
- Large gene content
- DNA and RNA analysis
- Fusion detection
- Broad solid-tumor profiling
Potential limitation
More genomic information also creates a greater need for appropriate interpretation and clinical context.
Clinical NGS Panel Comparison
| Test | Sample | Broad Profiling | Liquid Biopsy | Companion-Diagnostic Uses |
| FoundationOne CDx | Tissue | Yes | No | Yes |
| FoundationOne Liquid CDx | Blood | Yes | Yes | Yes |
| Guardant360 CDx | Blood | Yes | Yes | Yes |
| TruSight Oncology Comprehensive | Tissue | Yes | No | Yes |
This table is a starting point—not a substitute for checking the current test labeling and the patient's specific clinical circumstances.
Regulatory indications change over time, and a test authorized for one biomarker-treatment combination should not automatically be assumed to have the same status for another.
How Much Does Clinical NGS Cost?
Pricing can vary dramatically depending on the laboratory, panel size, specimen type, insurance coverage, geographic market, and whether the test is clinically indicated.
There is rarely one meaningful universal price.
The out-of-pocket cost can also differ substantially from the laboratory's billed amount.
Potential cost components include:
- Laboratory testing
- Pathology review
- Tissue preparation
- Blood collection
- Genetic counseling, where applicable
- Additional confirmatory testing
- Interpretation
- Repeat testing
- Insurance deductible or coinsurance
For healthcare organizations, the total financial equation is broader.
A comprehensive panel may cost more upfront but potentially reduce the need for multiple sequential tests.
Conversely, ordering a very broad panel when only a narrow clinical question exists may create unnecessary expense and interpretation burden.
The Best Cost Question to Ask
Instead of asking only:
"How much is this NGS test?"
ask:
"What is the expected total patient cost, what does the laboratory actually report, and which clinical decisions can this test potentially inform?"
That produces a much more useful comparison.
Is a Premium Oncology NGS Panel Worth It?
Sometimes.
A premium comprehensive test may be worthwhile when:
- The cancer is advanced or metastatic
- Standard treatment options are limited
- Multiple biomarkers could affect therapy
- Tissue is limited and sequential testing would be inefficient
- Clinical-trial matching is important
- A broad molecular picture could influence the treatment strategy
A narrower test may be more sensible when:
- The clinical question is highly specific
- A particular biomarker is already suspected
- A validated single-marker test is sufficient
- Additional findings would not change management
The goal is not to maximize the number of genes tested.
The goal is to obtain clinically useful information at a reasonable total cost.
Mini Case Study: When Broad Testing Can Save Time
Consider a patient with metastatic cancer whose initial treatment options are narrowing.
The team could order several individual molecular tests sequentially.
That approach may require multiple tissue preparations, laboratory workflows, and waiting periods.
Alternatively, an appropriately selected comprehensive NGS panel could assess multiple relevant biomarkers in one workflow.
If the broad test identifies an actionable alteration, the team may avoid some additional testing.
But there is an important caveat:
Broad testing only creates value when the results are interpreted correctly and can influence a real clinical decision.
That is why the laboratory's reporting quality and the treating team's expertise matter almost as much as the sequencing technology.
What Can Go Wrong With Clinical NGS?
NGS is powerful, but it is not infallible.
Insufficient Tissue
A biopsy may contain too little tumor material for reliable analysis.
Tumor Heterogeneity
Different parts of the same tumor can contain different molecular alterations.
Low Variant Fraction
Some mutations may be present at very low levels and can be difficult to detect reliably.
False Positives and False Negatives
Laboratory methods include quality controls and validation procedures, but no diagnostic test should be treated as perfect.
Variants of Uncertain Significance
A report may identify a genetic alteration whose clinical significance is not established.
This does not mean the patient has a targetable cancer mutation.
Incidental or Germline Findings
Some testing can raise questions about inherited genetic risk.
When germline implications are possible, appropriate clinical interpretation and genetic counseling may be important.
Common Mistakes to Avoid
Mistake 1: Choosing the Largest Panel Automatically
More genes do not necessarily mean better care.
Mistake 2: Treating Every Mutation as Actionable
A detected alteration may have limited, investigational, or uncertain clinical significance.
Mistake 3: Ignoring Specimen Quality
A sophisticated assay cannot compensate for an inadequate sample.
Mistake 4: Assuming Liquid Biopsy Replaces Tissue in Every Case
Liquid biopsy is valuable, but its performance depends on circulating tumor DNA and the clinical context.
Mistake 5: Comparing Prices Without Checking Coverage
A seemingly affordable test can become expensive if insurance coverage, deductibles, or additional testing are overlooked.
Mistake 6: Ignoring Regulatory Status
A test's authorization or clearance applies to particular intended uses. Always evaluate the actual indication rather than relying on a broad marketing description.
How to Choose a Trusted NGS Provider
Before selecting a laboratory or testing service, ask:
- Is the laboratory appropriately accredited for the jurisdiction in which the test is performed?
- What specimen types are accepted?
- Which genes and biomarkers are covered?
- Does the assay evaluate DNA, RNA, or both?
- Can it detect gene fusions and copy-number changes?
- What are the specimen requirements?
- What is the typical turnaround time?
- What happens if the specimen fails?
- Is the test FDA-authorized for the intended use, where applicable?
- How are uncertain findings reported?
- How are clinically relevant findings linked to treatment information?
- What happens to residual patient samples and genomic data?
- What are the billing and insurance policies?
- Is genetic counseling available when appropriate?
A trusted provider should be able to answer these questions clearly.
Clinical NGS Buying Checklist for Hospitals and Healthcare Organizations
If you are evaluating an oncology NGS service for a hospital, cancer center, laboratory, or healthcare business, assess five areas.
Clinical Performance
Look at validation, intended use, specimen requirements, and relevant detection capabilities.
Workflow
Consider ordering, accessioning, pathology review, sequencing, reporting, and integration with existing systems.
Cost
Calculate the complete cost—not merely the advertised laboratory charge.
Reporting
A technically excellent assay can still be frustrating if reports are difficult for clinicians to interpret.
Data Security
Genomic information is highly sensitive.
Evaluate:
- Data access controls
- Encryption
- Retention policies
- Data-sharing practices
- Storage location
- Patient privacy procedures
- Vendor contracts
What Is the Future of Clinical NGS?
The direction of oncology testing is moving toward increasingly integrated molecular profiling.
Rather than examining one biomarker at a time, clinical teams increasingly have access to combinations of:
DNA + RNA + pathology + imaging + circulating tumor DNA + clinical information
This could make molecular profiling more useful across diagnosis, treatment selection, resistance monitoring, and longitudinal disease management.
Liquid biopsy is also becoming increasingly important because blood collection is substantially easier to repeat than tissue biopsy in many circumstances.
Meanwhile, companion-diagnostic development continues to expand. The FDA's recent oncology regulatory activity includes additional NGS-based approvals and expanded indications for existing assays, illustrating how quickly the clinical testing landscape can change.
The practical implication is straightforward:
An oncology NGS test should be evaluated according to its current intended use, not simply its reputation or historical capabilities.
Final Verdict: Which Oncology NGS Panel Is Best?
There is no single best clinical NGS panel for every cancer patient or healthcare organization.
FoundationOne CDx is a strong option to consider when broad tissue profiling and its applicable companion-diagnostic indications fit the clinical question.
FoundationOne Liquid CDx and Guardant360 CDx are important liquid-biopsy options when blood-based testing is appropriate.
TruSight Oncology Comprehensive is compelling for organizations seeking broad DNA and RNA profiling in solid tumors, including relevant fusion detection.
But the "best" test is ultimately the one that answers the right clinical question with an appropriate specimen, validated methodology, interpretable reporting, and a defensible cost.
For patients, the decision belongs with the treating oncology team and qualified laboratory professionals.
For hospitals and healthcare buyers, compare the entire workflow—not just the gene count or laboratory price.
And for anyone evaluating commercial NGS services, remember the most important purchasing principle:
Don't buy the biggest panel. Buy the test that provides the most clinically useful information for the decision you actually need to make.
FAQ
What is an oncology NGS panel?
An oncology NGS panel is a laboratory test that analyzes multiple genes or genomic biomarkers simultaneously to identify alterations that may have diagnostic, prognostic, therapeutic, or clinical-trial relevance.
Is NGS better than single-gene testing?
Not always. NGS can be more efficient when multiple biomarkers are clinically relevant, but a focused test may be appropriate when there is a specific, well-defined clinical question.
What is the difference between tissue NGS and liquid biopsy?
Tissue NGS analyzes material obtained from a tumor, while liquid biopsy generally analyzes circulating tumor-derived DNA or other nucleic acids found in blood. Each has advantages and limitations.
Which is better, FoundationOne or Guardant360?
Neither is universally better. FoundationOne CDx is a tissue-based assay, while Guardant360 CDx is blood-based. The appropriate choice depends on the cancer, available specimen, biomarker question, and applicable test indication.
What does an NGS oncology panel test for?
Depending on the assay, it may detect mutations, insertions/deletions, copy-number changes, gene fusions, MSI, TMB, or other molecular biomarkers.
How much does an oncology NGS test cost?
There is no universal price. Patient responsibility depends on the laboratory, test, insurance coverage, deductible, specimen requirements, and other factors. Healthcare organizations should evaluate total cost of testing rather than the laboratory charge alone.
Can an NGS test find a cancer treatment?
An NGS test can identify a biomarker associated with a treatment option in appropriate circumstances. It does not guarantee that a treatment will work.
Does a negative liquid biopsy rule out a mutation?
No. A negative blood-based result can occur when there is insufficient circulating tumor DNA. Depending on the clinical situation, tissue testing may still be considered.
Are all NGS mutations actionable?
No. Some alterations have established treatment relevance, some have emerging evidence, and others may have uncertain or currently limited clinical significance.
How long does clinical NGS take?
Turnaround times vary by laboratory, specimen, assay, and workflow. A healthcare provider or laboratory should provide the expected timeframe for the specific test being ordered.
Is clinical NGS safe?
NGS is a laboratory diagnostic technology, so the physical risk is generally associated with obtaining the specimen rather than sequencing itself. Tissue biopsy can have procedure-related risks, while blood collection is typically less invasive. Genomic privacy and interpretation are also important considerations.
Should every cancer patient have comprehensive NGS?
No. The usefulness of comprehensive profiling depends on cancer type, stage, treatment history, available therapies, specimen quality, and the clinical question. Testing should be selected by the treating clinical team based on the individual circumstances.
What should I ask before ordering an oncology NGS test?
Ask what the test detects, which specimen is required, whether it is authorized for the intended clinical use, how results are interpreted, what the total cost may be, what happens if the specimen fails, and how genomic data are handled.
No comments:
Post a Comment